Page last updated: 2024-11-10

capillarisin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

capillarisin: from Artemisiae capillaris Herba.; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5281342
CHEMBL ID4475774
CHEBI ID3368
SCHEMBL ID13906076
MeSH IDM0057294

Synonyms (24)

Synonym
56365-38-9
capillarisin
C08999 ,
A831018
2-(p-hydroxyphenoxy)-6-methoxy-5,7-dihydroxychromone
capillarisine
5,7-dihydroxy-2-(4-hydroxyphenoxy)-6-methoxychromen-4-one
AC1NQYDG ,
FT-0640377
X1106 ,
5,7-dihydroxy-2-(4-hydroxyphenoxy)-6-methoxy-chromen-4-one
5,7-dihydroxy-2-(4-hydroxy-phenoxy)-6-methoxychromone
CHEBI:3368
SCHEMBL13906076
Q-100652
DTXSID30204918
CHEMBL4475774
Q27106050
5,7-dihydroxy-2-(4-hydroxyphenoxy)-6-methoxy-4h-chromen-4-one
MS-24653
HY-121192
CS-0080783
GLXC-18065
AKOS040761458

Research Excerpts

Overview

Capillarisin is a naturally isolated chromone. It is one of the major bioactive constituents of Artemisia capillaries.

ExcerptReferenceRelevance
"Capillarisin is a naturally isolated chromone, which is one of the major bioactive constituents of Artemisia capillaries. "( Capillarisin augments anti-oxidative and anti-inflammatory responses by activating Nrf2/HO-1 signaling.
Choi, HJ; Jung, K; Kang, BY; Kim, J; Lim, J, 2017
)
3.34

Effects

Capillarisin has antioxidant, anti-inflammatory, and anti-tumor potential. It has been found to suppress PMA-induced MMP-9 expression through inhibition of the NF-kappaB-dependent transcriptional activity.

ExcerptReferenceRelevance
"Capillarisin has extensive pharmacological properties and has been considered to have promising ant-inflammatory and anti-nociceptive activities."( Anti-hyperalgesic and anti-allodynic activities of capillarisin via suppression of inflammatory signaling in animal model.
Choi, JS; Choi, RJ; Chun, J; Islam, MN; Khan, S; Kim, YS; Park, S; Shehzad, O, 2014
)
1.38
"Capillarisin has antioxidant, anti-inflammatory, and anti-tumor potential, but the underlying molecular mechanisms remain largely unclear."( Capillarisin augments anti-oxidative and anti-inflammatory responses by activating Nrf2/HO-1 signaling.
Choi, HJ; Jung, K; Kang, BY; Kim, J; Lim, J, 2017
)
2.62
"Capillarisin has been found to suppress PMA-induced MMP-9 expression through inhibition of the NF-kappaB-dependent transcriptional activity of MMP-9 gene via p38 MAPK and JNK signaling pathways."( Suppression of PMA-induced tumor cell invasion by capillarisin via the inhibition of NF-kappaB-dependent MMP-9 expression.
Jeong, YJ; Kim, CH; Kim, M; Lee, IS; Lee, SO, 2008
)
1.32

Treatment

Pre-treatment of capillarisin strongly inhibited NF-κB mediated genes (iNOS, COX-2), involved in pain. Treatment with capilarisin reduced the mRNA and protein levels of iNOS and COx-2 in RAW 264.7 cells.

ExcerptReferenceRelevance
"Pre-treatment of capillarisin strongly inhibited NF-κB mediated genes (iNOS, COX-2), involved in pain."( Anti-hyperalgesic and anti-allodynic activities of capillarisin via suppression of inflammatory signaling in animal model.
Choi, JS; Choi, RJ; Chun, J; Islam, MN; Khan, S; Kim, YS; Park, S; Shehzad, O, 2014
)
0.98
"Treatment with capillarisin reduced the mRNA and protein levels of iNOS and COX-2 in RAW 264.7 cells as assessed by RT-PCR and Western blot."( Molecular mechanism of capillarisin-mediated inhibition of MyD88/TIRAP inflammatory signaling in in vitro and in vivo experimental models.
Choi, JS; Choi, RJ; Islam, MN; Khan, S; Kim, HP; Kim, YS; Shehzad, O, 2013
)
1.04
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
coumarins
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1546502Growth inhibition of human DU145 cells at 200 uM after 24 hrs by WST-1 assay relative to control2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID1546503Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 3 days by XTT assay2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (4.17)18.7374
1990's2 (8.33)18.2507
2000's4 (16.67)29.6817
2010's13 (54.17)24.3611
2020's4 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.55 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index5.17 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (96.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]